Astria Therapeutics to Present at Upcoming Jefferies Global Healthcare Conference

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will participate in a fireside chat at the upcoming Jefferies Global Healthcare Conference on Wednesday, June 4th at 1:25pm ET.

A webcast of the presentation can be accessed at the following link: https://wsw.com/webcast/jeff319/atxs/1878784. An archived replay of the presentation will be available in the investors section of www.astriatx.com for 30 days following the event.

About Astria Therapeutics:

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is an investigational monoclonal antibody OX40 antagonist in clinical development for the treatment of atopic dermatitis. Learn more about our company on our website, www.astriatx.com, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn.

Contacts

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  218.72
-3.31 (-1.49%)
AAPL  260.06
-2.70 (-1.03%)
AMD  238.63
+0.60 (0.25%)
BAC  51.12
-0.41 (-0.79%)
GOOG  255.41
+4.07 (1.62%)
META  739.33
+6.06 (0.83%)
MSFT  523.40
+5.74 (1.11%)
NVDA  182.55
+1.39 (0.77%)
ORCL  275.00
-0.15 (-0.05%)
TSLA  440.94
-1.66 (-0.38%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.